Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Tony van Werkhooven who wrote (603)	3/4/1999 8:34:00 PM
From: yosi s	Read Replies (2) \| Respond to of 1386

CONGRATS TO PHARMOS ON GREAT Q 4 RELEASE. Pharmos always stated that 99 will be at a loss, unless hu211 partner cames in, at best they hoped for is for Q4 99 to bring in neutral cash flow. The gearing up statement is what I have been waiting for. They are setting up ground work. Overall it is a great looking forward statement. Movement on a number of fronts. 1.Le tobra nda application 2.Sales growth of Alrex and Lotemax. 3.partner for HU 211. it sounds like Head trauma and Stroke are going to be on together. I would like to see : 1.month to month Alrex and Lotemax growth. 2. Marketing of Alrex to allergist. 3. progress on NDA Alrex and Lotemax in Europe. 4. How much of convertible stocks remains. Shares out standing went from 37 million 12/98 to 40 million in March 99.